1. 2010
  2. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia

    Zhang, W., Kater, A. P., Widhopf, G. F., Chuang, H-Y., Enzler, T., James, D. F., Poustovoitov, M., Tseng, P-H., Janz, S., Hoh, C., Herschman, H., Karin, M. & Kipps, T. J., 2010, In: Proceedings of the National Academy of Sciences of the United States of America. 107, 44, p. 18956-18960

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

    Tromp, J. M., Tonino, S. H., Elias, J. A., Jaspers, A., Luijks, D. M., Kater, A. P., van Lier, R. A. W., van Oers, M. H. J. & Eldering, E., 2010, In: Oncogene. 29, 36, p. 5071-5082

    Research output: Contribution to journalArticleAcademicpeer-review

  4. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

    Tonino, S. H., van Gelder, M., Eldering, E., van Oers, M. H. & Kater, A. P., 2010, In: Leukemia. 24, 3, p. 652-654

    Research output: Contribution to journalComment/Letter to the editorAcademic

  5. Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study

    Kater, A. P. & Tonino, S. H., 2010, In: Clinical lymphoma, myeloma & leukemia. 10, Suppl. 1, p. S34-S41

    Research output: Contribution to journalArticleAcademicpeer-review

  6. 2009
  7. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression

    Enzler, T., Kater, A. P., Zhang, W., Widhopf, G. F., Chuang, H-Y., Lee, J., Avery, E., Croce, C. M., Karin, M. & Kipps, T. J., 2009, In: Blood. 114, 20, p. 4469-4476

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction

    Mous, R., Jaspers, A., Luijks, D. M. P., Mellink, C. H. M., van Oers, M. H. J., Kater, A. P. & Eldering, E., 2009, In: Leukemia. 23, 7, p. 1352-1355

    Research output: Contribution to journalComment/Letter to the editorAcademic

  9. De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie

    Kater, A. P. & van Oers, M. H. J., 2009, In: Nederlands tijdschrift voor hematologie. 6, 8, p. 317-320

    Research output: Contribution to journalArticleProfessional

  10. miR-34a as part of the resistance network in chronic lymphocytic leukemia

    Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Bühler, A., Kienle, D., Winkler, D., Dürig, J., van Oers, M. H. J., Mertens, D., Döhner, H. & Stilgenbauer, S., 2009, In: Blood. 113, 16, p. 3801-3808

    Research output: Contribution to journalArticleAcademicpeer-review

  11. 2008
  12. De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie

    Kater, A. P. & van Oers, M. H. J., 2008, In: Nederlands tijdschrift voor hematologie. 5, 6, p. 236-244

    Research output: Contribution to journalArticleProfessional

ID: 64520